FindTrial
Sign In

A Retrospective Analysis on the Outcomes of Myeloma Patients with Del(17p) or TP53 Mutation in Asia

A Retrospective Analysis on the Outcomes of Myeloma Patients with Del(17p) or TP53 Mutation in Asia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127743
Enrollment
Unknown
Registered
2026-07-07
Start date
2026-07-10
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Observational group:Nonw

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Individuals who are 18 years old or older; 2.Diagnosed with active myeloma according to 2014 IMWG criteria (10) from 1st Jan 2015 to 31st Dec 2025; 3.Patient must have measurable disease (quantifiable serum or urine M-protein) on diagnosis (defined as serum M protein>=0.5 g/dL or 24-hour urine M-protein excretion >=200mg or dFLC >=10 mg/dL (>=100 mg/L) or an abnormal serum free light chain ratio (1.65);

Exclusion criteria

Exclusion criteria: 1.Patients diagnosed with symptomatic amyloidosis, Waldenstrom macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes); 2.Patients enrolled in clinical trials during any time point of their treatment;

Design outcomes

Primary

MeasureTime frame
Response Rate;Median Duration of Response;Progression-Free Survival;Overall Survival;—

Secondary

MeasureTime frame
Prognostic Factors for Overall Survival;Minimal Residual Disease-Negative Rate After Treatment;Response Assessment by PET-CT;—

Countries

China

Contacts

Public ContactZhuang Junling

Peking Union Medical College Hospital

zhuangjunling@hotmail.com+86 10 69155027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026